FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

3 Groups Sue to Block Drug Import Rule

[ Price : $8.95]

Three healthcare groups sue the Trump administration to block an HHS/FDA final rule that would permit some drug importation from C...

CGMP Issues at AuroLife Pharma New Jersey Facilities

[ Price : $8.95]

FDA warns AuroLife Pharma about CGMP violations at two of its New Jersey drug manufacturing facilities.

Final Guide on Drug Development Tools

[ Price : $8.95]

FDA posts a final guidance on Qualification Process for Drug Development Tools Guidance for Industry and FDA Staff.

Alnylam Pharma NDA for Oxlumo Approved

[ Price : $8.95]

FDA approves an Alnylam Pharmaceuticals NDA for Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria Type 1 (PH1), ...

ANDA Complex Product Meeting Guidance

[ Price : $8.95]

FDA issues a guidance to assist ANDA applicants for complex products to schedule and conduct several types of meetings with agency...

Panelists Review CDRH Digital Health Goals

[ Price : $8.95]

CDRH holds a second listening session on its new Digital Health Center of Excellence and examines whether it is pursuing the most ...

Expiration Date Extended for 42 Cutaquig Lots

[ Price : $8.95]

FDA extends from 24 to 36 months the expiration date for 42 lots of Cutaquig if they are stored at a cooler temperature.

Neuronetics TouchStar Protocol Cleared for Depression

[ Price : $8.95]

FDA clears a Neuronetics 510(k) for its TouchStar treatment, a three-minute intermittent theta burst protocol for use with its Neu...

FDA Recognizes ANSI Accreditation Board for ASCA Pilot

[ Price : $8.95]

FDA recognizes the ANSI board as an accreditation body for the agencys Accreditation Scheme for Conformity Assessment pilot projec...

Latest FDA Warning Letter

[ Price : $8.95]

FDA releases its latest batch of Warning Letters that includes one medical product company AuroLife Pharma.